Document is current
Any future updates will be listed below
-
Authors
Rudrapatna, Vivek A. https://orcid.org/0000-0003-1789-3004
Ravindranath, Vignesh G.
Arneson, Douglas V.
Mosenia, Arman
Butte, Atul J. https://orcid.org/0000-0002-7433-2740
Wang, Shan
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | U.S. National Library of Medicine (K99LM014099)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (5T32DK007007)
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (TR001872)
- License Information
-
More Information
Article History
Received: 21 June 2024
Accepted: 8 April 2025
First Online: 31 May 2025
Competing interests
: VAR received grant support from Janssen, Alnylam, Merck, Genentech, Takeda, and Blueprint Medicines for unrelated work during this study. VGR is currently employed by Epic Systems Corporation. DVA is currently an employee at Bristol Myers Squibb. AM has no potential conflicts to disclose. AJB is a co-founder and consultant to Personalis and NuMedii; consultant to Mango Tree Corporation, and in the recent past, Samsung, 10x Genomics, Helix, Pathway Genomics, and Verinata (Illumina); has served on paid advisory panels or boards for Geisinger Health, Regenstrief Institute, Gerson Lehman Group, AlphaSights, Covance, Novartis, Genentech, and Merck, and Roche; is a shareholder in Personalis and NuMedii; is a minor shareholder in Apple, Meta (Facebook), Alphabet (Google), Microsoft, Amazon, Snap, 10x Genomics, Illumina, Regeneron, Sanofi, Pfizer, Royalty Pharma, Moderna, Sutro, Doximity, BioNtech, Invitae, Pacific Biosciences, Editas Medicine, Nuna Health, Assay Depot, and Vet24seven, and several other non-health related companies and mutual funds; and has received honoraria and travel reimbursement for invited talks from Johnson and Johnson, Roche, Genentech, Pfizer, Merck, Lilly, Takeda, Varian, Mars, Siemens, Optum, Abbott, Celgene, AstraZeneca, AbbVie, Westat, and many academic institutions, medical or disease specific foundations and associations, and health systems. Atul Butte receives royalty payments through Stanford University, for several patents and other disclosures licensed to NuMedii and Personalis. Atul Butte’s research has been funded by NIH, Peraton (as the prime on an NIH contract), Genentech, Johnson and Johnson, FDA, Robert Wood Johnson Foundation, Leon Lowenstein Foundation, Intervalien Foundation, Priscilla Chan and Mark Zuckerberg, the Barbara and Gerson Bakar Foundation, and in the recent past, the March of Dimes, Juvenile Diabetes Research Foundation, California Governor’s Office of Planning and Research, California Institute for Regenerative Medicine, L’Oreal, and Progenity. SW has no potential conflicts to disclose. The authors declare that no actual competing interests exist.
